Benzoyl peroxide/clindamycin low dose - Stiefel Laboratories

Drug Profile

Benzoyl peroxide/clindamycin low dose - Stiefel Laboratories

Alternative Names: Benzoyl peroxide 3%/clindamycin 1%; CLDM 1%-BPO 3% gel; Clindamycin/benzoyl peroxide; Clindoxyl ADV Gel; Duac low dose; Duac Low Dose; Duac® 3% Gel; Duac® Combination Gel; GSK 2585823; Indoxyl

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stiefel Laboratories
  • Class Antiacnes; Antibacterials; Benzoic acids; Lincosamides; Oxidants; Small molecules
  • Mechanism of Action Keratinocyte inhibitors; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 23 Jun 2015 No recent reports on development identified - Preregistration for Acne vulgaris in USA (Topical)
  • 26 Mar 2015 Registered for Acne vulgaris in Japan (Topical)
  • 04 Mar 2013 The United Kingdom's Medicine and Healthcare products Regulatory Agency recommends approval of Benzoyl peroxide/clindamycin for Acne vulgaris in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top